Abstract
Background Omalizumab is a humanized anti-immunoglobulin E (IgE) monoclonal antibody that has been approved as add-on therapy for the treatment of adults with moderate-tosevere (United States) or severe (Europe) allergic asthma, inadequately controlled after treatment with high-dose inhaled corticosteroids plus long-acting b-agonists. The clinical efficacy of Omalizumab has not only been shown in the treatment of severe uncontrolled asthma, but also in the treatment of nasal polyposis and comorbid asthma. The aim of this analysis was to examine whether the diagnosis of chronic rhinosinusitis (CRS) influenced the asthma response to Omalizumab treatment.
Highlights
Omalizumab is a humanized anti-immunoglobulin E (IgE) monoclonal antibody that has been approved as add-on therapy for the treatment of adults with moderate-tosevere (United States) or severe (Europe) allergic asthma, inadequately controlled after treatment with high-dose inhaled corticosteroids plus long-acting b-agonists
The mean age of the patients was 54.4 years and 62% of them were female. 84.3% of the asthmatics responded to Omalizumab treatment
A higher Staphylococcal enterotoxins (SE)-IgE concentration was found in patients with chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and a strong correlation between SE-IgE and total IgE was observed
Summary
Omalizumab is a humanized anti-immunoglobulin E (IgE) monoclonal antibody that has been approved as add-on therapy for the treatment of adults with moderate-tosevere (United States) or severe (Europe) allergic asthma, inadequately controlled after treatment with high-dose inhaled corticosteroids plus long-acting b-agonists. The clinical efficacy of Omalizumab has been shown in the treatment of severe uncontrolled asthma, and in the treatment of nasal polyposis and comorbid asthma. The aim of this analysis was to examine whether the diagnosis of chronic rhinosinusitis (CRS) influenced the asthma response to Omalizumab treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
